Re-irradiation for Recurrent Skin Cancer
Radiotherapy has an important role in the management of patients with cutaneous malignancy. Non-melanoma skin cancer (NMSC) is the most frequent malignancy worldwide, and as such the absolute number of patients receiving radiotherapy each year is high. An often and well-documented scenario is the development of a second NMSC, if not within a previous radiotherapy field, certainly in close proximity to a previous radiotherapy field, and therefore there may be a requirement to consider overlapping any new radiotherapy field with previously irradiated tissue, if other options are not considered. Published evidence for cutaneous re-irradiation is sparse especially as other options such as surgery are often available. Despite this select patients may be considered for re-irradiation, be that local or occasionally regional, especially where other options are not feasible.
KeywordsSentinel Lymph Node Biopsy Basal Cell Carcinoma Stereotactic Body Radiotherapy Merkel Cell Carcinoma Biological Equivalent Dose
- Ferro M, Deodata F, Macchia G et al (2015) Short-course radiotherapy in elderly patients with early stage non-melanoma skin cancer: A phase 2 study. Cancer Invest 33:34–38Google Scholar
- Gunaratne D, Howle J, Veness MJ (2016) Sentinel lymph node biopsy in Merkel cell carcinoma: a 15 year institutional experience and statistical analysis of 721 reported cases. BJD 174:273–281Google Scholar
- Henderson MA, Burmeister BH, Ainslie J et al (2015) Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 16:1049–1060CrossRefPubMedGoogle Scholar
- Porceddu S, Veness M, Guminski A (2015) Non-melanoma cutaneous head and neck cancer and Merkel cell carcinoma – Current concepts, advances and controversies. J Clin Oncol 33:3338–3345Google Scholar
- Smith TL, Morris CG, Mendenhall NP (2014) Angiosarcoma after breast-conserving therapy: Long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol 53:235–241Google Scholar